CRBP Live-Signale | Maximieren Sie Profite mit Getagraph.com

VERKAUFEN 107783 min ago

@ $23.69

Ausgestellt: 14 Feb 2024 @ 15:41

Rendite: 44.58%

Vorheriges Signal: Feb 13 - 15:30

Vorheriges Signal: Kaufen

Rendite: 11.15 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 22:00):

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases...

Stats
Tagesvolumen	96 876.00
Durchschnittsvolumen	404 033
Marktkapitalisierung	359.39M
EPS	$0 ( 2024-03-12 )
Nächstes Ertragsdatum	( $-1.090 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.32
ATR14	$0.107 (0.31%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-10	Moran Sean F.	Buy	1 787	Common Stock
2024-04-10	Moran Sean F.	Sell	1 787	Employee Stock Option (right to buy)
2024-03-08	Cormorant Asset Management, Lp	Buy	8 862	Common Stock
2024-03-08	Cormorant Asset Management, Lp	Buy	156 597	Common Stock
2024-03-08	Cormorant Asset Management, Lp	Buy	61 668	Common Stock

INSIDER POWER
99.57
Last 95 transactions
Buy: 14 080 389 \| Sell: 365 661

Volumen Korrelation

Lang: -0.13 (neutral)

Kurz: -0.68 (moderate negative)

Signal:(47.691) Neutral

Corbus Pharmaceuticals Korrelation

10 Am meisten positiv korreliert
VKTX	0.923
BLPH	0.919
CHMA	0.904
BTF	0.903
ALBO	0.902
SUMO	0.901
CMPI	0.901
NVCN	0.899
IMRX	0.885
NLTX	0.885

10 Am meisten negativ korreliert
MSBI	-0.949
BWFG	-0.948
NFBK	-0.946
CNOB	-0.944
ONB	-0.944
PFBC	-0.944
FBIZ	-0.943
PGC	-0.943
BCBP	-0.941
WSFS	-0.941

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Corbus Pharmaceuticals Korrelation - Währung/Rohstoff

-0.34
( neutral )

-0.28
( neutral )

0.59
( weak )

0.25
( neutral )

0.49
( neutral )

0.46
( neutral )

Corbus Pharmaceuticals Finanzdaten

Annual	2023
Umsatz:	$0
Bruttogewinn:	$-641 000 (0.00 %)
EPS:	$-10.31

FY	2023
Umsatz:	$0
Bruttogewinn:	$-641 000 (0.00 %)
EPS:	$-10.31

FY	2022
Umsatz:	$0
Bruttogewinn:	$-1.49M (0.00 %)
EPS:	$-13.39

FY	2021
Umsatz:	$881 705
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-0.370

Financial Reports:

No articles found.

Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.